Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04035226 · ClinicalTrials.gov registry record
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
A clinical trial of Multiple Myeloma, sponsored by Janssen-Cilag.
- Completed
- Registry status
- 254
- Enrollment target
- 20
- Study locations
NCT04035226: Completed study of Multiple Myeloma, sponsored by Janssen-Cilag.
NCT04035226 is a study of Multiple Myeloma that has completed, run by Janssen-Cilag. The registered enrollment target is 254 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04035226, a study of Multiple Myeloma, has completed, sponsored by Janssen-Cilag.
- COMPLETED
- Registry status
- 254 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).
Primary Outcome
ORR is defined as the percentage of patients who achieve a partial response (PR) or better according to the international myeloma working group (IMWG) response criteria.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (20)
Other
- Grand Hopital de Charleroi, site Notre Dame - Charleroi
- Universitair Ziekenhuis Antwerpen - Edegem
- UZ Leuven - Leuven
- Ucl de Mont-Godinne - Yvoir
- Centre Hospitalier du Mans - Le Mans
- Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez - Lille
- CHU de Montpellier Hopital Saint Eloi - Montpellier
- C.H.U. Hotel Dieu - France - Nantes
California
- Oncology Institute of Hope and Innovation - Glendale
- Marin Cancer Center - Greenbrae
Missouri
- Central Care Cancer Center - Bolivar
- Washington University School Of Medicine - St Louis
New York
- The Cancer Institute at St. Francis Hospital - East Hills
- North Shore Hematology Oncology Associates, P.C. - East Setauket
Florida
- Asclepes Research - Weeki Wachee
Illinois
- Oncology Hematology Assoc of Central Illinois, P.C. d.b.a. Illinois CancerCare, P.C. - Peoria
Michigan
- Providence Cancer Center - Southfield
Nevada
- Optum Care - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2019-08-02 |
| Est. Completion | 2022-10-27 |
What the finished NCT04035226 record still lists
NCT04035226 is an observational study that tracks outcomes without assigning an intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT04035226 names 20 study sites across 10 states, led by Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT04035226 about?
NCT04035226 is a clinical study titled "A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment". The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).
What is the current status of trial NCT04035226?
This trial is currently completed. The enrollment target is 254 participants. The study started on 2019-08-02. Estimated completion is 2022-10-27.
What conditions does trial NCT04035226 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04035226?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04035226?
This trial is sponsored by Janssen-Cilag, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04035226 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04035226's enrollment target sits among peer trials
254 87th of 438 higher than 352 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI